EGFR (OMIM 131550) variants and ALK (OMIM 105590) rearrangements are the 2 most common targetable alterations in NSCLC; as of 2020, eight targeted therapies were approved by the US Food and Drug Administration (FDA) to treat patients with tumors harboring these alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.